Adagrasib

Drug Overview

Adagrasib is a breakthrough targeted therapy designed to treat cancers driven by a specific genetic mutation that was historically considered “undruggable.” It belongs to the class of KRAS inhibitors, marking a significant advancement in precision oncology for patients with non-small cell lung cancer and colorectal cancer.

• Generic Name: Adagrasib
• US Brand Names: Krazati®
• Drug Class: KRAS G12C Inhibitor (Small Molecule)
• Route of Administration: Oral (Tablets)
• FDA Approval Status: Accelerated approval for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).

What Is It and How Does It Work? (Mechanism of Action)

Adagrasib functions by locking a mutated protein into an inactive state, thereby shutting down the signals that cause cancer cells to multiply uncontrollably.

• Molecular Target: The drug selectively targets the KRAS G12C mutant protein. The KRAS protein normally acts as an on/off switch for cell growth. In the G12C mutation (where glycine is replaced by cysteine at position 12), the switch gets stuck in the “on” position, driving tumor growth.
• Covalent Locking: Adagrasib binds covalently (irreversibly) to the mutant cysteine residue in the KRAS G12C protein. Crucially, it binds only when the protein is in its inactive (GDP-bound) state. By locking it in this inactive form, adagrasib prevents the protein from being reactivated, effectively turning the switch “off”.
• Pathway Inhibition: This blockade stops downstream signaling through the MAPK/ERK pathway, leading to the arrest of cell proliferation and the induction of apoptosis (cell death) in tumor cells harboring this specific mutation.

FDA-Approved Clinical Indications

Adagrasib is FDA-approved for adult patients with specific solid tumors that have progressed after prior treatments.

Oncological Uses:

• Non-Small Cell Lung Cancer (NSCLC): Indicated for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy.
• Colorectal Cancer (CRC): Indicated in combination with cetuximab for adult patients with KRAS G12C-mutated locally advanced or metastatic CRC who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Non-Oncological Uses:

• There are no FDA-approved non-oncological indications.

Dosage and Administration Protocols

Adagrasib is administered orally. The capsules or tablets must be swallowed whole.

Standard Oncology Dosage:

• Dose: 600 mg (typically three 200 mg tablets) taken orally twice daily.
• Frequency: Twice daily (BID).
• Administration: Swallow whole with or without food. Take at the same time each day.

Dose Modifications for Toxicity:

• First Reduction: 400 mg twice daily.
• Second Reduction: 600 mg once daily.
• Discontinue: If 600 mg once daily is not tolerated.

Organ Function Adjustments:

• Renal Impairment: No dose adjustment needed for mild to moderate impairment. Safety in severe impairment has not been established.
• Hepatic Impairment: No specific adjustment defined in standard labeling, but hepatotoxicity requires dose interruption/reduction.

Clinical Efficacy and Research Results

Clinical trials from 2020-2025 demonstrate adagrasib’s efficacy in difficult-to-treat mutations, showing high response rates and central nervous system (CNS) activity.

• NSCLC Efficacy (KRYSTAL-1): In the pivotal phase 2 trial, adagrasib monotherapy showed an Objective Response Rate (ORR) of 43% and a Disease Control Rate (DCR) of 80% in previously treated patients. The median Overall Survival (OS) was 12.6 months, with a median Progression-Free Survival (PFS) of 6.5 months.
• CNS Penetration: Uniquely among KRAS inhibitors, adagrasib has demonstrated significant intracranial activity, with a 33% intracranial response rate in patients with active, untreated brain metastases, addressing a critical unmet need in lung cancer.
• Colorectal Cancer: In combination with cetuximab, adagrasib showed superior efficacy compared to monotherapy, with response rates improving significantly due to the blockade of feedback loops that often limit KRAS inhibitor efficacy in the colon.

Safety Profile and Side Effects

Important Warnings:

Adagrasib carries warnings for Gastrointestinal Toxicity, QTc Interval Prolongation, Hepatotoxicity, and Interstitial Lung Disease (ILD).

Common Side Effects (>25%)

• Gastrointestinal: Diarrhea (very common, ~70%), nausea, vomiting, and decreased appetite.
• General: Fatigue, musculoskeletal pain, and edema.
• Laboratory Abnormalities: Decreased hemoglobin, decreased leukocytes, increased creatinine, and increased liver enzymes (ALT/AST).
• Renal: Renal impairment (increased creatinine) is frequently observed.

Serious Adverse Events

• Hepatotoxicity: Drug-induced liver injury can occur. Monitor liver enzymes monthly for the first 3 months.
• QTc Prolongation: Can lead to life-threatening arrhythmias. Avoid co-administration with other QTc-prolonging drugs.
• Interstitial Lung Disease (ILD): Rare but fatal pneumonitis. Patients with a new cough or dyspnea must be evaluated immediately.

Management Strategies:

• For Diarrhea: Initiate antidiarrheals (e.g., loperamide) at the first sign of loose stools. Hydration is critical.
• For QTc Prolongation: Monitor ECG and electrolytes (potassium/magnesium) regularly. Hold dose if QTc > 500 ms.

Connection to Stem Cell and Regenerative Medicine

Adagrasib targets the KRAS pathway, a fundamental regulator of cell fate and proliferation.

• Inhibiting Cancer Stemness: Research suggests that KRAS mutations drive the “stemness” or self-renewal capacity of cancer cells. By inhibiting this driver, adagrasib may deplete the population of cancer stem cells (CSCs) responsible for tumor recurrence and metastasis.
• Overcoming Resistance: Studies are investigating how adagrasib can reverse multidrug resistance (MDR) mediated by ABC transporters (efflux pumps) often found on cancer stem cells, potentially re-sensitizing tumors to other chemotherapy agents.

Patient Management & Practical Recommendations

Pre-Treatment Tests:

• KRAS G12C Mutation Testing: Mandatory confirmation using an FDA-approved test (plasma or tissue).
• Liver Function Tests (LFTs): Baseline AST, ALT, alkaline phosphatase, and total bilirubin.
• Electrocardiogram (ECG): Baseline ECG to check QTc interval and electrolytes.

Precautions During Treatment:

• Drug Interactions: Adagrasib is a substrate of CYP3A4. Avoid strong CYP3A4 inducers (e.g., rifampin) and inhibitors. It can also increase the levels of other drugs (e.g., digoxin).
• GI Management: Patients should be advised to eat small, bland meals to manage nausea and to stay hydrated.

Do’s and Don’ts:

• DO: Take the medication at the same time every day.
• DO: Swallow tablets whole; do not crush or chew.
• DON’T: Take an extra dose if you vomit after taking it; wait for the next scheduled dose.
• DON’T: Ignore symptoms like dizziness or palpitations (potential heart rhythm issues).

Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.